N/A N=314 Randomized Diagnostic

Spaeth/Richman Contrast Sensitivity Test

Glaucoma

Bottom Line

View on ClinicalTrials.gov: NCT01300949 ↗

Enrolled (actual)

314

Serious AEs

0.0%

Results posted

Nov 2018

Primary outcome: Primary: Contrast Sensitivity, Another Means of Testing Vision — 59.4; 74.4; 53.9 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Spaeth/Richman Contrast Sensitivity Test (Diagnostic_test); Pelli-Robson Contrast Sensitivity Chart (Diagnostic_test)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Wills Eye
Primary completion: Apr 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Contrast Sensitivity, Another Means of Testing Vision	59.4; 74.4; 53.9	—

Summary

The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test, another way to measure vision, is performed on any standard computer with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson contrast test.

Eligibility Criteria

Inclusion Criteria

18 yrs of age and older
able to provide fully informed consent

70 controls (patients with no ocular disease affecting visual acuity or visual function), 10 from each decade of life: 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80+.

105 patients with ocular hypertension or any type of glaucoma (15 subjects per age decade). Glaucoma patients will not have macular degeneration or visual acuity affected by any function other than glaucoma.

40 patients with macular degeneration: 10 with visual acuity 20/40 or better, 10 with visual acuity between 20/40 and 20/60, 10between 20/100 and 20/400, and 10 with 20/400 or worse.

40 patients with cataracts: 10 with lens opacity 1+nuclear sclerosis, 10 with 2 + nuclear sclerosis, 10 with 3 + nuclear sclerosis, 10 with 4 + nuclear sclerosis.

60 patients with refractive error: 10 with myopia -5 diopters or greater, 10 with myopia between -5 and -2.5, 10 with myopia between -2.5 and -0.5, 10 with myopia between -0.5 and 0.5, 10 with myopia between 0.5 and 2.5, and 10 with myopia > 2.5.

Exclusion Criteria

any other diseases affecting visual acuity

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01300949). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.